Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer.

[1]  E. Scarpi,et al.  Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide , 2020, Frontiers in Oncology.

[2]  J. Schalken,et al.  A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA–Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate Cancer , 2020 .

[3]  Jianjun Yu,et al.  Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer. , 2020, European urology.

[4]  O. Elemento,et al.  Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. , 2020, The Journal of clinical investigation.

[5]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[6]  A. Wyatt,et al.  Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. , 2019, JCO precision oncology.

[7]  E. Scarpi,et al.  Testosterone levels and androgen receptor copy number variations in castration‐resistant prostate cancer treated with abiraterone or enzalutamide , 2019, The Prostate.

[8]  E. Scarpi,et al.  Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. , 2019, European journal of cancer.

[9]  N. Agarwal,et al.  Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. , 2019, The New England journal of medicine.

[10]  G. Pond,et al.  Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer , 2019, Cancer.

[11]  E. Scarpi,et al.  Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis. , 2019, JCO precision oncology.

[12]  B. Trock,et al.  Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer , 2019, JCO precision oncology.

[13]  E. Scarpi,et al.  Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer , 2019, European urology.

[14]  V. Conteduca,et al.  Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test , 2018, Prostate Cancer and Prostatic Diseases.

[15]  D. Olmos,et al.  Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study) , 2018, British Journal of Cancer.

[16]  Liewei Wang,et al.  Prognostic association of plasma cell free DNA based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration resistant prostate cancer patients , 2018, Prostate Cancer and Prostatic Diseases.

[17]  J. Vandesompele,et al.  Prognostic and Therapeutic Implications of Circulating Androgen Receptor Gene Copy Number in Prostate Cancer Patients Using Droplet Digital Polymerase Chain Reaction , 2017, Clinical genitourinary cancer.

[18]  E. Scarpi,et al.  Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer , 2017, Scientific Reports.

[19]  D. Amadori,et al.  Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Matti Nykter,et al.  Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. , 2016, JAMA oncology.

[21]  E. Scarpi,et al.  Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer , 2016, Oncotarget.

[22]  Delila Gasi Tandefelt,et al.  Plasma AR and abiraterone-resistant prostate cancer , 2015, Science Translational Medicine.

[23]  D. Amadori,et al.  Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone , 2015, British Journal of Cancer.

[24]  Martin E. Gleave,et al.  Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer , 2015, Clinical Cancer Research.

[25]  M. Nykter,et al.  Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. , 2018, Cancer discovery.